Chemical Biology and Drug Design

DECEMBER 19, 2024

The new palmitoylated derivatives of thioglycolic acid are designed to mimic microbial lipopeptides as a new class of small-molecule immunomodulators. The current study includes a new design of palmitoylated derivatives of thioglycolic acids (PTGAs) capable of triggering innate immune responses.

Small Molecule 100

Small Molecule Immune Response Research 100

Drug Target Review

APRIL 7, 2025

Involved in various physiological processes, such as vision, taste, smell, immune response and neurotransmission, GPCRs are activated by various molecules including hormones, neurotransmitters and environmental stimuli, which trigger a cascade of cellular events that help regulate bodily functions.

Fragment Screening 52

Fragment Screening Drugs Small Molecule Biophysical Assays 52

Drug Target Review

NOVEMBER 6, 2023

These regimens frequently include one or two small molecule inhibitors and immuno-oncology (IO) therapies, such as monoclonal antibodies and T-cell engagers. This article was written and developed by AstraZeneca. These options are creating opportunities to develop more sophisticated, novel combination regimens for patients.

Small Molecule 111

Small Molecule Therapies Treatment Disease 111

Drug Target Review

JULY 11, 2023

In this article, I spoke to Olivia Cavlan, Chief Corporate Development and Strategy Officer at Alchemab Therapeutics Ltd, about how AI is transforming the landscape of disease research, unlocking a treasure trove of knowledge that may hold the key to a healthier future. Cavlan will explore more of these ends in our next article.

Disease 75

Disease RNA Small Molecule Clinical Development 75

LifeSciVC

MARCH 1, 2023

Such is the story of targeting casitas B-lineage lymphoma-B (CBL-B) that was highlighted in a recent scientific review article published in the Journal for ImmunoTherapy of Cancer. Even good ideas are met with healthy skepticism for the practical and technical limitations of being able to effectively test a hypothesis.

Small Molecule 52

Small Molecule Immune Response DNA Therapies 52

Drug Target Review

DECEMBER 13, 2024

Typically, these combinations include an immune checkpoint inhibitor (CPI; eg, anti-programmed cell death protein 1 [PD-1] / programmed cell death ligand 1 [PD-L1]) combined with other components such as chemotherapy, a targeted small molecule drug, novel CPIs, or ADCs.

Therapies 98

Therapies Treatment Clinical Trials Drugs 98

New Drug Approvals

DECEMBER 16, 2023

3 Additionally, iptacopan has the benefit of targeting factor B, which only affect the alternative complement pathway, leaving the classic and lectin pathway untouched for the body to still mount adequate immune responses against pathogens. of patients experienced a sustained hemoglobin improvement without transfusions respectively.

FDA 62

FDA Small Molecule FDA Approval Treatment 62